JP2023539493A5 - - Google Patents
Info
- Publication number
- JP2023539493A5 JP2023539493A5 JP2023513582A JP2023513582A JP2023539493A5 JP 2023539493 A5 JP2023539493 A5 JP 2023539493A5 JP 2023513582 A JP2023513582 A JP 2023513582A JP 2023513582 A JP2023513582 A JP 2023513582A JP 2023539493 A5 JP2023539493 A5 JP 2023539493A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- binding fragment
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063072113P | 2020-08-29 | 2020-08-29 | |
| US63/072,113 | 2020-08-29 | ||
| PCT/EP2021/073816 WO2022043538A1 (en) | 2020-08-29 | 2021-08-27 | Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539493A JP2023539493A (ja) | 2023-09-14 |
| JP2023539493A5 true JP2023539493A5 (enExample) | 2024-09-03 |
Family
ID=77821706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513582A Pending JP2023539493A (ja) | 2020-08-29 | 2021-08-27 | Ｂｃｌ－２阻害剤への低下した感度を有する患者の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240182590A1 (enExample) |
| EP (1) | EP4204098A1 (enExample) |
| JP (1) | JP2023539493A (enExample) |
| KR (1) | KR20230061421A (enExample) |
| CN (1) | CN116249519A (enExample) |
| AU (1) | AU2021334165A1 (enExample) |
| CA (1) | CA3188634A1 (enExample) |
| IL (1) | IL300996A (enExample) |
| MX (1) | MX2023002318A (enExample) |
| WO (1) | WO2022043538A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| AU2023390486A1 (en) * | 2022-12-08 | 2025-07-03 | The Regents Of The University Of Colorado, A Body Corporate | Methods for identifying resistance or response to venetoclax/hypomethylating agent/anti-cd70 agent treatment for acute myeloid leukemia |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1594542T3 (da) | 2003-02-20 | 2010-10-11 | Seattle Genetics Inc | Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer |
| US20080025989A1 (en) * | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| AU2007333098A1 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind CD70 and uses thereof |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| KR101923364B1 (ko) | 2010-11-23 | 2018-11-30 | 애브비 인코포레이티드 | 아폽토시스유도제의 염 및 결정형 |
| US10391168B1 (en) * | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
| US11001582B2 (en) | 2016-03-10 | 2021-05-11 | Assia Chemical Industries Ltd. | Solid state forms of Venetoclax and processes for preparation of Venetoclax |
| WO2017212431A1 (en) | 2016-06-09 | 2017-12-14 | Dr. Reddy’S Laboratories Limited | Solid forms of venetoclax and processes for the preparation of venetoclax |
| EP3481397A1 (en) | 2016-07-06 | 2019-05-15 | Concert Pharmaceuticals Inc. | Deuterated venetoclax |
| CN107648185A (zh) | 2016-07-25 | 2018-02-02 | 常州爱诺新睿医药技术有限公司 | 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法 |
| WO2018029711A2 (en) | 2016-08-12 | 2018-02-15 | Mylan Laboratories Limited | Process for the preparation of venetoclax |
| US10800777B2 (en) | 2016-10-14 | 2020-10-13 | Mylan Laboratories Limited | Polymorphic forms of VENCLEXTA |
| EP3333167A1 (en) | 2016-12-09 | 2018-06-13 | LEK Pharmaceuticals d.d. | Solid forms of venetoclax |
| WO2018157803A1 (zh) | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | 维奈妥拉的晶型及其制备方法 |
| WO2018167652A1 (en) | 2017-03-13 | 2018-09-20 | Laurus Labs Limited | Process for preparation of amorphous form of venetoclax |
| CN107089981A (zh) | 2017-04-24 | 2017-08-25 | 杭州科耀医药科技有限公司 | 一种BCL‑2抑制剂Venetoclax的合成方法 |
| GB2567613A (en) | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
| TWI848030B (zh) * | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
-
2021
- 2021-08-27 EP EP21772989.6A patent/EP4204098A1/en active Pending
- 2021-08-27 IL IL300996A patent/IL300996A/en unknown
- 2021-08-27 CA CA3188634A patent/CA3188634A1/en active Pending
- 2021-08-27 JP JP2023513582A patent/JP2023539493A/ja active Pending
- 2021-08-27 KR KR1020237010275A patent/KR20230061421A/ko active Pending
- 2021-08-27 MX MX2023002318A patent/MX2023002318A/es unknown
- 2021-08-27 CN CN202180053199.2A patent/CN116249519A/zh active Pending
- 2021-08-27 WO PCT/EP2021/073816 patent/WO2022043538A1/en not_active Ceased
- 2021-08-27 AU AU2021334165A patent/AU2021334165A1/en active Pending
-
2023
- 2023-02-27 US US18/175,225 patent/US20240182590A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7317650B2 (ja) | Ｈｅｒ－３関連疾患を治療または予防するための物質および方法 | |
| Chen et al. | Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma | |
| US11225515B2 (en) | Macrophage stimulating protein receptor (or RON—recepteur d'Origine Nantais) antibodies and uses thereof | |
| Liu et al. | A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies | |
| JP2018508462A5 (enExample) | ||
| JP2023516936A5 (enExample) | ||
| ES2742079T3 (es) | Tratamiento de macroglobulinemia de Waldenström asociada a C1013G/CXCR4 con un anticuerpo anti-CXCR4 | |
| US10738119B2 (en) | Combination therapy for hepatocellular carcinoma | |
| CN110613845A (zh) | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 | |
| JP2017517507A5 (enExample) | ||
| JP2018517714A (ja) | 抗ｃｄ３７イムノコンジュゲートおよび抗ｃｄ２０抗体の組み合わせ | |
| JP2014523920A5 (enExample) | ||
| HK1248539A1 (zh) | 借助塞里班土单抗的组合治疗 | |
| JPWO2020040245A5 (enExample) | ||
| JP2022519649A (ja) | がんの診断および治療方法 | |
| KR20110140126A (ko) | 항-ｅｇｆｒ 작용제(들) 및 ｉｇｆ-1ｒ 특이적 억제제를 사용하는 조합 요법 | |
| AU2021334165A1 (en) | Method of treatment of patients having reduced sensitivity to a BCL-2 inhibitor | |
| US20210023211A1 (en) | Combination of anti-fgfr4-antibody and bile acid sequestrant | |
| JP2020500161A5 (enExample) | ||
| JP2021535110A (ja) | 併用療法 | |
| JP6368811B2 (ja) | 放射線感受性を調節するためのｈｅｒ３阻害剤 | |
| WO2017050240A1 (en) | Method to treat cancer using arginine delpetor and ornithine decarboxylase (odc) inhibitor | |
| KR20260022498A (ko) | 암의 치료 및 예방을 위한 조합물 | |
| Ali et al. | PRDX1 protects ATM from arsenite-induced proteotoxicity and maintains its stability during DNA damage signaling | |
| US20240148765A1 (en) | Compositions and methods for treating and/or preventing therapy-related cardiomyopathy associated with neutrophil infiltration |